Macular Degeneration News and Research

Latest Macular Degeneration News and Research

Tel Aviv researcher says lessons from Israel's health-care system could optimize eye health

According to the World Health Organization, 80% of blindness is preventable or treatable - but it remains a severe health concern across the globe, even in industrialized countries.

11 Jul 2013

Ohr Pharmaceutical enrolls first 60 patients in OHR-002 Phase II clinical trial for wet-AMD treatment

Ohr Pharmaceutical, Inc., a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced that it has enrolled the first 60 patients in the Company's ongoing OHR-002 Phase II clinical trial evaluating Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration.

10 Jul 2013

Research suggests new models for study of Barrett's esophagus

Research focused on the regulation of the adult stem cells that line the gastrointestinal tract of Drosophila suggests new models for the study of Barrett's esophagus.

28 Jun 2013

Ico Therapeutics completes Phase 2 iDEAL study for treatment of diabetic macular edema

iCo Therapeutics Inc. announced today that it has completed enrollment of its Phase 2 iDEAL study evaluating the efficacy and safety after repeated injections of iCo-007 in patients with Diabetic Macular Edema (DME). The study has shown a good safety profile with no drug-related serious adverse events to date.

19 Jun 2013

Eylea can ease vision problems for wet AMD patients

There is no cure for age-related macular degeneration, an eye disease that is the leading cause of vision loss and blindness in older Americans. Last year, the National Institutes of Health reported that two drugs injected into the eyes, Avastin and Lucentis, eased symptoms for sufferers, especially those in the advanced, "wet" stage of the disease, when blood vessels in the eye become swollen and leak fluids in the eye.

19 Jun 2013

Omeros gets regulatory clearance to begin Phase 1 clinical trial of OMS721

Omeros Corporation today announced that it has obtained regulatory clearance to start the Phase 1 clinical trial evaluating OMS721, the Company's lead human monoclonal antibody from its mannan-binding lectin-associated serine protease-2 (MASP-2) program.

13 Jun 2013

Effective method to restore sight to patients with blinding diseases

Researchers at the University of California, Berkeley, have developed an easier and more effective method for inserting genes into eye cells that could greatly expand gene therapy to help restore sight to patients with blinding diseases ranging from inherited defects like retinitis pigmentosa to degenerative illnesses of old age, such as macular degeneration

13 Jun 2013

Rapamycin improves cardiac function in mice suffering from age-related heart disease

Elderly mice suffering from age-related heart disease saw a significant improvement in cardiac function after being treated with the FDA-approved drug rapamycin for just three months.

11 Jun 2013

Aflibercept drug used for AMD shows no added benefit over current standard therapy

The drug aflibercept (trade name: Eylea) has been approved in Germany since November 2012 for the treatment of wet age-related macular degeneration (AMD). In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG) the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over the current standard therapy.

7 Jun 2013

Ophthalmologists warn that overexposure to sun's UV rays can cause temporary blindness

With the arrival of summer, when the sun's ultraviolet rays are strongest, ophthalmologists − medical doctors who specialize in the diagnosis, medical and surgical treatment of eye diseases and conditions − are warning the public that overexposure to these rays can burn the eyes' corneas and cause painful, temporary blindness.

4 Jun 2013

Ohr Pharmaceutical declares 1-for-3 reverse split of its outstanding common stock

Ohr Pharmaceutical, Inc. (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced a 1-for-3 reverse split of the Company's issued and outstanding common stock. The reverse stock split will be effective prior to the stock market opening on Monday, June 3, 2013.

3 Jun 2013

Perceptual learning may hold promise for improving visual functions in people with central vision loss

Perceptual learning techniques may provide a useful new approach to rehabilitation in patients with central vision loss-taking advantage of visual plasticity that persists even in old age, according to a special article in the June issue of Optometry and Vision Science, official journal of the American Academy of Optometry. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

28 May 2013

New study reveals another duet played by Notch and BMP signals

A small ensemble of musicians can produce an infinite number of melodies, harmonies and rhythms. So too, do a handful of workhorse signaling pathways that interact to construct multiple structures that comprise the vertebrate body.

15 May 2013

Fish oil supplements may not alter progression of age-related macular degeneration, say researchers

A large-scale National Eye Institute study has shown fish oil supplements containing omega-3 fatty acids do not alter the progression of age-related macular degeneration, says a national team of researchers including David M. Brown, M.D., an retina specialist at The Methodist Hospital who ran Houston's part of the study.

14 May 2013

New book proposes ways to help people see better with macular degeneration, low vision

Dr. Randolph C. Kinkade , a Connecticut optometrist and founding member of the International Academy of Low Vision Specialists, has written the Guide for Macular Degeneration Eyeglasses: Low Vision Treatment.

10 May 2013

New skin cancer drug successfully tested in humans

A new class of drug targeting skin cancer's genetic material has been successfully tested in humans for the first time, opening the way to new treatments for a range of conditions from skin cancers to eye diseases.

8 May 2013

ACT announces European phase I clinical trial for Stargardt's disease using retinal pigment epithelial cells

Advanced Cell Technology, Inc. a leader in the field of regenerative medicine, today announced treatment of the first patient in the third dosage cohort, and seventh patient overall, in its European Phase I clinical trial for Stargardt's macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).

26 Apr 2013

Acucela begins phase 2b/3 clinical trial of emixustat hydrochloride to treat GA associated with dry AMD

Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for sight threatening eye diseases, today announced that a phase 2b/3 clinical trial investigating emixustat hydrochloride in subjects with geographic atrophy associated with dry age-related macular degeneration has been initiated.

25 Apr 2013

Ceregene announces top-line data from CERE-12 Phase 2b clinical study for Parkinson's disease

Ceregene, Inc. today announced the top-line data from its double-blind, randomized, controlled Phase 2b clinical study of CERE-120 (AAV-neurturin), a gene therapy product designed to deliver the neurotrophic factor neurturin, for Parkinson's disease.

20 Apr 2013

Implant improves vision for patients suffering from macular degeneration

Physicians at the Virginia Commonwealth University Medical Center have become the first in Virginia to successfully implant a telescope in a patient's eye to treat macular degeneration.

16 Apr 2013

Macular Degeneration News and Research

Latest Macular Degeneration News and Research

Tel Aviv researcher says lessons from Israel's health-care system could optimize eye health

Ohr Pharmaceutical enrolls first 60 patients in OHR-002 Phase II clinical trial for wet-AMD treatment

Research suggests new models for study of Barrett's esophagus

Ico Therapeutics completes Phase 2 iDEAL study for treatment of diabetic macular edema

Eylea can ease vision problems for wet AMD patients

Omeros gets regulatory clearance to begin Phase 1 clinical trial of OMS721

Effective method to restore sight to patients with blinding diseases

Rapamycin improves cardiac function in mice suffering from age-related heart disease

Aflibercept drug used for AMD shows no added benefit over current standard therapy

Ophthalmologists warn that overexposure to sun's UV rays can cause temporary blindness

Ohr Pharmaceutical declares 1-for-3 reverse split of its outstanding common stock

Perceptual learning may hold promise for improving visual functions in people with central vision loss

New study reveals another duet played by Notch and BMP signals

Fish oil supplements may not alter progression of age-related macular degeneration, say researchers

New book proposes ways to help people see better with macular degeneration, low vision

New skin cancer drug successfully tested in humans

ACT announces European phase I clinical trial for Stargardt's disease using retinal pigment epithelial cells

Acucela begins phase 2b/3 clinical trial of emixustat hydrochloride to treat GA associated with dry AMD

Ceregene announces top-line data from CERE-12 Phase 2b clinical study for Parkinson's disease

Implant improves vision for patients suffering from macular degeneration

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Macular Degeneration News and Research

Latest Macular Degeneration News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in